Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696436 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,291
- Enrollment target
NCT00696436: Completed Phase 3 study, sponsored by Takeda.
NCT00696436 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,291 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00696436, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,291 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
Primary Outcome
The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Interventions
- DRUG Placebo
- DRUG Valsartan
- DRUG Olmesartan
- DRUG Azilsartan medoxomil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,291 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
What the finished NCT00696436 record still lists
NCT00696436 is an interventional study that assigns participants to a tested intervention. Its 1,291 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (67% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00696436 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00696436 about?
NCT00696436 is a clinical study titled "An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.". The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.
What is the current status of trial NCT00696436?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,291 participants. The study started on 2008-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00696436?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG), Olmesartan (DRUG), Azilsartan medoxomil (DRUG).
Who is sponsoring clinical trial NCT00696436?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00696436's enrollment target sits among peer trials
1,291 196th of 2000 higher than 1,805 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT06626022 · 1,284 participants · Phase 3
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia